Evidence-based feasibility
Population, denominator, time window, competing protocols, clinical workflow and resource assumptions are documented for each synopsis.
Pharma & CROs · Oncology · Russia
An oncology research team with 82 studies in the official GRLS record
Under Artem Poltoratskiy’s leadership, the research direction has operated since 2012. Each protocol receives a separate feasibility, patient-access, role-allocation and communication assessment.
Since 2012continuity of leadership and research processes
82 studieslisted in the official GRLS investigator profile
OncologyRussian and international sponsor studies
Protocol-specificfeasibility, resources and site profile
Sponsor value
A site is an operating system, not a single CV
Sponsors and CROs need realistic recruitment assumptions, accountable roles, timely escalation and reliable data—not decorative performance claims.
Patient access
Routine clinical flow and physician referrals can be complemented by patient education and carefully governed digital navigation.
Study readiness
Protocol review, role allocation, protocol-specific training and operational pathways are prepared before active recruitment.
Conduct and communication
Screening-log discipline, data and safety workflows, milestone review and named escalation support transparent collaboration.
Operating model
From synopsis to close-out
Protocol review
Clinical relevance, population, procedures, burden and critical-to-quality factors.
Feasibility
Documented assumptions, realistic forecast, competing studies and resource check.
Start-up
Roles, training, route maps, systems, safety and communication readiness.
Recruitment
Transparent patient sources, screening log, forecast-versus-actual review and corrective action.
Conduct & data
Protocol discipline, participant protection, timely data work and issue escalation.
Close-out
Resolution of outstanding actions, documentation and operational learning.
Methodology
How a modern oncology research team works
The full article explains feasibility denominators, recruitment funnels, role-based training, ICH E6(R3) quality by design and responsible use of digital tools.
It uses ICH, CTTI, FDA and peer-reviewed sources and deliberately avoids turning published recruitment ratios into local promises.
Development interface
From nonclinical evidence to clinical operations
Two source-linked explainers clarify how nonclinical evidence, product quality and clinical research fit together.
Preclinical drug development
Pharmacology, ADME and PK, toxicology, GLP, CMC and a coherent transition to first-in-human research.
Open guideGCP, GLP and GMP
A careful comparison of three quality systems and the claims that each cannot establish on its own.
Compare standardsProfessional contribution
Research culture and patient education
Artem is a founder of the National Association of Investigators and Research Organisations and contributes to education on clinical-trial methods and patient communication.
Patient webinars, professional forums and navigation projects help build informed routes to research. For a sponsor, these activities complement—but do not replace—protocol-specific capability, compliance and site evidence.
Next step
Send a synopsis or feasibility request
Use the general contact only for a non-confidential first enquiry. A current site profile, exact location, resources and documented track record can be provided for the specific protocol through an agreed channel.